白细胞介素36α对小鼠银屑病样皮损及趋化因子CCL20的影响

中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (4): 263-267.

白细胞介素36α对小鼠银屑病样皮损及趋化因子CCL20的影响

朱超英¹,温炬²,李婷¹,赵琪楠¹,秦思³,马静³,郑荣昌³,冯洁莹³

1. 南方医科大学附属广东省第二人民医院
2. 1.南方医科大学附属南粤医院广东省第二人民医院；2.广东省第二人民医院
3. 广东省第二人民医院

收稿日期:2016-08-08 修回日期:2016-09-14 出版日期:2017-04-15 发布日期:2017-03-31
通讯作者: 温炬 E-mail:wenju3139@163.com
基金资助:
广东省中医药局科研课题

Effects of interleukin?36α on psoriasiform skin lesions and C?C motif chemokine ligand 20 in mice

Received:2016-08-08 Revised:2016-09-14 Online:2017-04-15 Published:2017-03-31
Contact: Ju WEN E-mail:wenju3139@163.com

摘要/Abstract

摘要： 目的探讨白细胞介素（IL）36α对小鼠银屑病样皮损及CC趋化因子配体20（CCL20）的影响。方法 30只BALB/c雌性小鼠分为3组：凡士林空白对照组（对照组）、咪喹莫特模型组（模型组）以及IL?36α实验组（实验组）。用小鼠银屑病皮损面积和疾病严重程度评分（PASI）观察银屑病样小鼠皮损动态变化。光镜下观察皮损组织形态学变化，并测量表皮层厚度。用实时荧光定量PCR、 Western印迹检测对照组与模型组小鼠皮损中IL?36α表达情况，用实时荧光定量PCR、Western 印迹法、免疫组化方法检测小鼠皮损中CCL20的含量变化。结果模型组皮损中IL?36α mRNA表达水平明显高于对照组（?Ct值分别为0.0195 ± 0.0059、 0.0012 ± 0.0004，两组比较，P < 0.05）；模型组皮损中IL?36α蛋白表达水平明显高于对照组（分别为3.922 ± 0.248、0.690 ± 0.025，两组比较，P < 0.05）。对照组、实验组CCL20 mRNA表达（?Ct值）分别为0.378 ± 0.075、2.152 ± 0.793，与模型组（0.999 ± 0.178）比较，差异有统计学意义（P < 0.05）；对照组、实验组CCL20蛋白表达结果分别为0.025 ± 0.009、0.397 ± 0.033，与模型组（0.145 ± 0.030）比较，差异有统计学意义（P < 0.05）。免疫组化结果表明，实验组皮损中CCL20的含量较模型组显著增加，差异有统计学意义（Z = 2.294，P < 0.05）。结论 IL?36α可通过促进CCL20表达，加重银屑病样小鼠皮损病变。

Abstract: Zhu Chaoying, Wen Ju, Li Ting, Zhao Qinan, Qin Si, Ma Jing, Zheng Rongchang, Feng Jieying Department of Dermatology, Guangdong No.2 Provincial People′s Hospital, Affiliated to Southern Medical University, Guangzhou 510317, China Corresponding author: Wen Ju, Email: wenju3139@163.com 【Abstract】 Objective To evaluate effects of interleukin?36α （IL?36α） on psoriasiform skin lesions and C?C motif chemokine ligand 20 （CCL20） in mice. Methods Totally, 30 BALB/c female mice were randomly and equally divided into 3 groups: control group treated with topical vaseline cream on the shaved back and intracutaneous injection with phosphate buffer saline （PBS）, model group treated with topical imiquimod cream on the shaved back and intracutaneous injection with PBS, experimental group treated with topical imiquimod cream on the shaved back and intracutaneous injection with IL?36α solution. Psoriasis area severity index （PASI） was used to evaluate changes of psoriasiform skin lesions in mice, and light microscopy to observe morphological changes of skin lesions and to measure the thickness of the epidermis. Real?time fluorescence?based quantitative PCR （qRT?PCR） and Western blot analysis were performed to determine the of IL?36α in skin lesions in the control group and model group, and qRT?PCR, Western blot analysis and immunohistochemical study to evaluate changes of CCL20 levels in skin lesions. Results The model group showed significantly increased mRNA （?Ct value: 0.0195 ± 0.0059） and protein （3.922 ± 0.248） of IL?36α compared with the control group （mRNA: 0.0012 ± 0.0004, P < 0.05; protein: 0.690 ± 0.025, P < 0.05）. The mRNA and protein of CCL20 were significantly higher in the experimental group than those in the model group （mRNA: 2.152 ± 0.793 vs. 0.999 ± 0.178; protein: 0.397 ± 0.033 vs. 0.145 ± 0.030; both P < 0.05）, and higher in the model group than those in the control group （mRNA: 0.378 ± 0.075; protein: 0.025 ± 0.009; both P < 0.05）. Immunohistochemical study showed that the intensity of CCL20 in skin lesions significantly increased in the experimental group compared with that in the model group （Z = 2.294, P < 0.05）. Conclusion IL?36α may aggravate psoriasiform skin inflammation in mice by promoting CCL20 .

朱超英温炬李婷赵琪楠秦思马静郑荣昌冯洁莹. 白细胞介素36α对小鼠银屑病样皮损及趋化因子CCL20的影响[J]. 中华皮肤科杂志, 2017, 50(4): 263-267.doi:

参考文献 17

［1］	Nishida A, Hidaka K, Kanda T, et al. Increased of interleukin⁃36, a member of the interleukin⁃1 cytokine family, in inflammatory bowel disease［J］. Inflamm Bowel Dis, 2016, 22（2）: 303⁃314. DOI: 10.1097/MIB.0000000000000654.
［2］	El MK, Karbach SH, Huppert J, et al. An alternative pathway of imiquimod⁃induced psoriasis⁃like skin inflammation in the absence of interleukin⁃17 receptor a signaling［J］. J Invest Dermatol, 2013, 133（2）: 441⁃451. DOI: 10.1038/jid.2012.318.
［3］	Towne JE, Sims JE. IL⁃36 in psoriasis［J］. Curr Opin Pharmacol, 2012, 12（4）: 486⁃490. DOI: 10.1016/j.coph.2012.02.009.
［4］	Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL⁃36⁃mediated DC⁃keratinocyte crosstalk［J］. J Clin Invest, 2012, 122（11）: 3965⁃3976. DOI: 10.1172/JCI63451.
［5］	Friedrich M, Tillack C, Wollenberg A, et al. IL⁃36γ sustains a proinflammatory self⁃amplifying loop with IL⁃17C in anti⁃TNF⁃induced psoriasiform skin lesions of patients with Crohn′s disease［J］. Inflamm Bowel Dis, 2014, 20（11）: 1891⁃1901. DOI: 10.1097/ MIB.0000000000000198.
［6］	Foster AM, Baliwag J, Chen CS, et al. IL⁃36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin［J］. J Immunol, 2014, 192（12）: 6053⁃6061. DOI: 10.4049/jimmunol. 1301481.
［7］	Bozoyan L, Dumas A, Patenaude A, et al. Interleukin⁃36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis［J］. J Neuroinflammation, 2015, 12: 173. DOI: 10.1186/s12974⁃015⁃0392⁃7.
［8］	Ciccia F, Accardo⁃Palumbo A, Alessandro R, et al. Interleukin⁃36α axis is modulated in patients with primary Sjögren′s syndrome［J］. Clin Exp Immunol, 2015, 181（2）: 230⁃238. DOI: 10.1111/cei.12644.
［9］	Lv Z, Fan J, Zhang X, et al. Integrative genomic analysis of interleukin⁃36RN and its prognostic value in cancer［J］. Mol Med Rep, 2016, 13（2）: 1404⁃1412. DOI: 10.3892/mmr.2015.4667.
［10］	Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL⁃1 family members in gut health and disease［J］. Front Immunol, 2013, 4: 181. DOI: 10.3389/fimmu.2013. 00181.
［11］	赵京霞, 底婷婷, 王燕, 等. IL⁃23/IL⁃17炎症轴在咪喹莫特诱导的小鼠银屑病样皮肤损害中的作用［J］. 中国病理生理杂志, 2013, 29（6）: 1086⁃1094. DOI: 10.3969/j.issn.1000⁃4718.2013. 06.023.
［12］	舒丹, 苏飞, 晋红中. 白介素36与银屑病［J］. 中华皮肤科杂志, 2013, 46（7）: 519⁃522. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.07.023.
［13］	Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll⁃like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors［J］. Arch Dermatol, 2004, 140（12）: 1490⁃1495. DOI: 10.1001/archderm.140.12.1490.
［14］	Blumberg H, Dinh H, Dean C, et al. IL⁃1RL2 and its ligands contribute to the cytokine network in psoriasis［J］. J Immunol, 2010, 185（7）: 4354⁃4362. DOI: 10.4049/jimmunol.1000313.
［15］	Ramadas RA, Ewart SL, Iwakura Y, et al. IL⁃36α exerts pro⁃inflammatory effects in the lungs of mice［J］. PLoS One, 2012, 7（9）: e45784. DOI: 10.1371/journal.pone.0045784.
［16］	Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses［J］. Annu Rev Immunol, 2000, 18: 593⁃620. DOI: 10.1146/annurev.immunol.18.1.593.
［17］	马怡莹, 魏志平, 刘彦群. 卡马拉素对HaCaT细胞体外增殖及对白细胞介素17C、CCL20、NF⁃κB表达的影响［J］.中华皮肤科杂志, 2015, 48（7）: 475⁃479. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.07.009.